Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

27.08.24	Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH (Roche Holding AG)
20.08.24	Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak (Roche Holding AG)
30.07.24	Roche: European Commission Approves Vabysmo For Treatment Of Retinal Vein Occlusion (RTTNews)
30.07.24	European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) (Roche Holding AG)
29.07.24	Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care (Roche Holding AG)
25.07.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter - full-year earnings outlook raised (Roche Holding AG)
18.07.24	New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions (Roche Holding AG)
18.07.24	Roche's Vabysmo Shows Long-Term Durability, Efficacy, Safety In Diabetic Macular Edema Study (RTTNews)
17.07.24	Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study (Roche Holding AG)
17.07.24	Roche Announces Positive Phase I Results Of CT-996 For Obesity Treatment (RTTNews)
17.07.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity (Roche Holding AG)
16.07.24	Roche Canada: Health Canada Approves Alecensaro Monotherapy As Adjuvant Treatment (RTTNews)
09.07.24	Roche Obtains CE Mark For AI-enabled Continuous Glucose Monitoring Solution (RTTNews)
09.07.24	Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes (Roche Holding AG)
08.07.24	Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) (Roche Holding AG)
05.07.24	FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss (Roche Holding AG)
04.07.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer (Roche Holding AG)
28.06.24	Roche's PiaSky Gets Positive Recommendation From CHMP For Treatment Of PNH (RTTNews)
28.06.24	Roche: Vabysmo Gets CHMP Recommendation For Third Indication - Quick Facts (RTTNews)
28.06.24	Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) (Roche Holding AG)
28.06.24	CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition (Roche Holding AG)
27.06.24	Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection (Roche Holding AG)
25.06.24	Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis (Roche Holding AG)
24.06.24	Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories (Roche Holding AG)
21.06.24	Sarepta Therapeutics' Elevidys Approved By FDA For Duchenne Muscular Dystrophy; Stock Surges (RTTNews)
20.06.24	Roche Unveils Advanced Test For Enhanced B-Cell Lymphoma Diagnosis (RTTNews)
20.06.24	Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma (Roche Holding AG)
18.06.24	Roche Obtains FDA Clearance On Digital Pathology Solution For Diagnostic Use (RTTNews)
16.06.24	Roche : Phase III Study Of Columvi Combo Extends Survival In Relapsed Diffuse Large B-Cell Lymphoma (RTTNews)
15.06.24	Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
14.06.24	Lixte, Roche, Netherlands Cancer Institute Collaborate For Colon Cancer Trial; Stock Up (RTTNews)
10.06.24	European Commission Approves Roche's Alecensa For ALK-positive Early-stage Lung Cancer (RTTNews)
10.06.24	Roche's 4-in-1 Test For COVID, Flu, RSV Gets FDA Emergency Use Nod (RTTNews)
10.06.24	Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization (Roche Holding AG)
10.06.24	European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer (Roche Holding AG)
07.06.24	Genentech's 5-Year Data Of Evrysdi Shows Improvement In Type 1 Spinal Muscular Atrophy Patients (RTTNews)
07.06.24	Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk (Roche Holding AG)
29.05.24	FDA Grants Priority Review To Genentech's Inavolisib For Advanced HR+, HER2- Breast Cancer Mutation (RTTNews)
29.05.24	FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
27.05.24	Hitachi High-Tech, Roche Extend Partnership (RTTNews)
27.05.24	Changes to the Roche Enlarged Corporate Executive Committee (Roche Holding AG)
22.05.24	Roche: FDA Grants Breakthrough Device Designation For Bood Test Measuring Lp(a) (RTTNews)
22.05.24	Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) - a key marker for hereditary cardiovascular risk (Roche Holding AG)
21.05.24	Roche, Genentech: Inavolisib Gets FDA Breakthrough Status To Treat Breast Cancer With Mutation (RTTNews)
21.05.24	FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
16.05.24	Roche's Phase I Trial Of CT-388 To Treat Obesity And Type 2 Diabetes Report Positive Results (RTTNews)
16.05.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity (Roche Holding AG)
15.05.24	FDA Approves Roche's HPV Self-Collection Solution In Cervical Cancer (RTTNews)
15.05.24	Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer (Roche Holding AG)
24.04.24	Hookipa Received FDA Clearance For HB-700 For Treatment Of KRAS-Mutated Cancers (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

25.06.24		Roche kann EU-Zulassung für Multiple-Sklerose-Mittel an Land ziehen - Aktie sinkt dennoch
10.06.24		Roche-Aktie dennoch tiefer: EU-Kommission lässt Lungenkrebsmedikament Alecensa zu
21.05.24		Roche-Aktie schwächer: Roche-Übernahme von LumiraDx in prüfung - Inavolisib erhält "Breakthrough Therapy"-Status
11.12.23		Roche-Aktie etwas fester: Roche legt Studiendaten zu Kadcyla, Hemlibra, Columvi und Lunsumio vor
02.02.23		Roche-Aktie schwächer: Roche erreicht 2022 Prognose - Umsatz- und Gewinnrückgang im neuen Jahr erwartet
27.12.22		Roche-Aktie leichter: FDA lässt Roches Lymphom-Behandlung Lunsumio zu
16.09.22		Roche-Aktie gewinnt: Moody's hebt Bonitätseinstufung für Roche an
25.04.22		Roche-Aktie leichter: Umsatz übertrifft Erwartungen